Caisse de depot et placement du Quebec Invests $86.53 Million in Illumina, Inc. $ILMN

Caisse de depot et placement du Quebec purchased a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, Holdings Channel.com reports. The institutional investor purchased 492,139 shares of the life sciences company’s stock, valued at approximately $86,533,000.

A number of other hedge funds and other institutional investors have also modified their holdings of ILMN. HighPoint Advisor Group LLC grew its position in Illumina by 3.7% in the 4th quarter. HighPoint Advisor Group LLC now owns 2,218 shares of the life sciences company’s stock valued at $291,000 after buying an additional 80 shares in the last quarter. Elevation Wealth Partners LLC raised its position in shares of Illumina by 52.5% during the 2nd quarter. Elevation Wealth Partners LLC now owns 244 shares of the life sciences company’s stock worth $43,000 after buying an additional 84 shares in the last quarter. Meeder Advisory Services Inc. lifted its stake in shares of Illumina by 3.1% in the 1st quarter. Meeder Advisory Services Inc. now owns 2,822 shares of the life sciences company’s stock worth $348,000 after acquiring an additional 85 shares during the period. Toronto Dominion Bank lifted its stake in shares of Illumina by 0.3% in the 4th quarter. Toronto Dominion Bank now owns 33,605 shares of the life sciences company’s stock worth $4,407,000 after acquiring an additional 92 shares during the period. Finally, Panagora Asset Management Inc. boosted its holdings in shares of Illumina by 3.9% in the fourth quarter. Panagora Asset Management Inc. now owns 2,536 shares of the life sciences company’s stock valued at $333,000 after acquiring an additional 96 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ILMN. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price objective on the stock in a research note on Thursday, May 14th. Deutsche Bank Aktiengesellschaft downgraded Illumina to a “hold” rating in a research report on Wednesday, August 5th. Barclays upped their price objective on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a report on Friday, July 31st. Guggenheim raised their target price on Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Finally, Citigroup lifted their target price on Illumina from $95.00 to $113.00 and gave the stock a “sell” rating in a report on Monday, August 3rd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have issued a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Illumina has an average rating of “Hold” and an average target price of $188.40.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $227.69 on Friday. The company has a market capitalization of $34.38 billion, a PE ratio of 42.48, a price-to-earnings-growth ratio of 3.16 and a beta of 1.45. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The stock has a fifty day moving average of $192.98 and a 200-day moving average of $155.18. Illumina, Inc. has a one year low of $88.00 and a one year high of $231.81.

Illumina (NASDAQ:ILMN) last announced its earnings results on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, beating the consensus estimate of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the prior year, the business posted $1.19 earnings per share. Illumina’s revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insider Buying and Selling at Illumina

In other news, Director Keith A. Meister sold 138,379 shares of the business’s stock in a transaction that occurred on Thursday, August 27th. The shares were sold at an average price of $228.89, for a total transaction of $31,673,569.31. Following the sale, the director owned 1,033,910 shares in the company, valued at $236,651,659.90. The trade was a 11.80% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 2,034,688 shares of company stock valued at $417,970,281. 2.90% of the stock is currently owned by corporate insiders.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.